MedTrace Logo

Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.

NCT03643575 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin

Conditions

  • Healthy Subjects

Interventions

DRUG

Vicks Cough Syrup for Chesty Coughs

Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water

DRUG

Robitussin Extra Strength Chest Congestion

Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water

DRUG

Organ-I- NR tablet

Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water

Sponsors & Collaborators

  • Reckitt Benckiser Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-07-16
Completion
2009-07-16
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03643575 on ClinicalTrials.gov